HIGHLIGHTS
- who: Josep-Maria Ribera and Sabina Chiaretti from the Universitat Autu00f2noma de Barcelona, Badalona, Barcelona, Spain Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome have published the research: Modern Management Options for Ph+ ALL, in the Journal: Cancers 2022, 14, 4554. of 18/07/2022
- what: The achievement of a complete molecular response (CMR) at 10-12 weeks from the beginning of therapy emerged as a major prognostic factor for patients treated with TKI and intensive or attenuated therapy and constitutes one of the main objectives of the therapy . An . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.